Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 1.41B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -395.89M |
| Shares Out | 224.24M |
| EPS (ttm) | -2.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,083,643 |
| Open | 6.35 |
| Previous Close | 6.33 |
| Day's Range | 6.21 - 6.39 |
| 52-Week Range | 5.42 - 18.73 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 22.70 (+260.89%) |
| Earnings Date | May 4, 2023 |
About IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is $22.7, which is an increase of 260.89% from the latest price.
News
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno...
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report...
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy
3 Graham's Lost Formula Picks to Consider for the New Year
After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation...
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
Despite a rough day in the market over fears that the Federal Reserve may raise interest rates and thus induce a recession, biopharmaceutical startup Iovance Biotherapeutics (NASDAQ: IOVA) stock shot...
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
Iovance's stock is down after receiving FDA feedback on application for new melanoma drug
Shares of Iovance Biotherapeutics Inc. IOVA, -2.61% fell 11.4% in premarket trading on Friday after the company said it received feedback from the Food and Drug Administration on its submission for li...
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration BLA Submission Ongoing with U.S. Food and Drug Administration
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report...
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 Oral Presentation of C-144-01 Trial Cohorts 2 and 4
Iovance Biotherapeutics to Present Posters at ESMO 2022
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno...
5 Top Stocks Cathie Wood Is Selling This Week
Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail inve...
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 202...
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track in August 2022